XML Financial LLC Sells 452 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

XML Financial LLC trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 592 shares of the biopharmaceutical company’s stock after selling 452 shares during the quarter. XML Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $25,000. Rakuten Securities Inc. boosted its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $28,000. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $36,000. Finally, Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on REGN shares. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating for the company in a research note on Friday, April 25th. UBS Group reduced their price objective on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a “neutral” rating for the company in a research note on Thursday, June 5th. Royal Bank Of Canada downgraded Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price objective for the company. in a report on Friday, May 30th. Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $958.00 to $755.00 and set an “overweight” rating on the stock in a report on Monday, June 2nd. Finally, BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating for the company in a research report on Monday, June 2nd. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $836.48.

Regeneron Pharmaceuticals Price Performance

REGN opened at $511.92 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The firm has a market cap of $55.27 billion, a P/E ratio of 13.03, a PEG ratio of 1.87 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a 50-day moving average of $557.15 and a 200 day moving average of $638.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same period last year, the firm posted $9.55 EPS. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.69%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.